ABSTRACT
Background: COVID-2019 caused by SARS-CoV-2 has become a pandemic that has claimed more than 6.2 million lives so far. Vaccination is the most effective tool in the fight against infectious diseases. However, low vaccination coverage is hampering our efforts to contain the COVID- 19 pandemic. Vaccine side effects are one of the reasons for reluctance to vaccinate. In this study, we systematically investigated self-reported vaccine side effects (SE) after the first, second, and booster vaccinations. Method(s): The data was collected during the TuSeRe:exact Study (Tubinger Monitoring Studie zur exakten Analyze der Immunantwort nach Vakzinierung). The coworkers from University Hospital Tubingen, Center for Clinical Transfusion Medicine and Natural and Medical Sciences Institute were invited to participate in the study. Study participants were asked to fill an online questionnaire and report SE after first, second and booster vaccinations. Result(s): A total of 889 participants (mean age: 43 +/- 12.7 years;female: n= 664 (77%), male: n= 205 (23%)) were included in the analysis. Pain on injection site was the most common local SE after first, second and booster vaccination (68%, 70%, 57%, respectively). Fatigue was the most common systemic SE after first, second and booster vaccination (61%, 64%, 46%, respectively). Local and systemic SE were highest after vector based vaccine ChAdOx1 nCoV-19 in the 1. vaccination. However, local and systemic SE were more common after mRNA vaccines (BNT162b2, mRNA-1273) in the 2. vaccination. Compared to BNT162b2 vaccine, more SE have been observed after mRNA-1273 vaccine in the booster vaccination. Conclusion(s): Local and systemic SE are common after SARS-CoV-2 vaccines. The frequency of self-reported local and systemic SE are significantly different between mRNA and vector vaccines. SE are more common after mRNA-1273 vaccine than BNT162b2 vaccine.
ABSTRACT
Nicknamed "SARS Stock," the event celebrated the end of the severe acute respiratory syndrome 1 (SARS-CoV-1) outbreak2 But Grant Johnson, MLT, team leader of microbiology at The Hospital for Sick Children at the time, was not at the concert. [...]Health Canada approved several in early 2020.3 CJMLS spoke to Johnson and laboratory professionals at another Canadian hospital to learn how incorporating Cepheid's GeneXpert,a popular rapid PCR box testing platform, has affected the work of laboratory professionals and patient care and how they managed issues that arose with it during the COVID-19 pandemic. Available in various sizes ranging from two to 16 modules, the GeneXpert platform can process tests for different indications simultaneously, making "on-demand molecular testing available to everyone with unprecedented speed and ease of use," according to the company's marketing materials.3 Preparation time is about five to seven minutes, and results are available within about 50 minutes.4 For example, the Cepheid GeneXpert Xpert Xpress SARS-CoV-2 assay targets two genome regions on the virus, the envelope and the nucleocapsid. Test results for individual patients confirmed whether they needed to isolate to prevent infecting others or if it was safe for them to visit loved ones, such as those in long-term care facilities with a higher risk of severe disease and mortality from SARS-CoV-2 infection.
ABSTRACT
Objective: This article analyzes the epidemic situation and characteristics of Corona virus disease 2019 (COVID-19) in Russian Federation (referred to as Russia). summarizes the effective measures and problems exposed by Russia to deal with COVID-19, so as to provide reference for our country's epidemic prevention and control, and seek the direction of cooperation under the background of Sino Russia scientific and technological innovation in view of public health emergency.
ABSTRACT
Aim: The presence of neutralizing antibodies (NAbs) is an indicator of protective immunity for most viral infections. This study investigated the detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) neutralizing antibodies NAbs (IgM & IgG) following vaccination with three common potential vaccines (Pfizer, AstraZeneca and Sino pharm), in Nasiriya city /south of Iraq. Methods. From September 2021 to April 2022.158 participants who had completed COVID-19 vaccination (50 persons for each) were recruited and tested using Covid-19 neutralizing antibody kits, for NAbs evaluation. Results. Majority of the participants were 21-40 years old of age. NAbs were observed in 100% of enrolled individuals (vaccinated or not) but with significant difference in the IgM and IgG titers in correlate to the vaccine type, but there weren't with other demographic factors effect. Nine days after second vaccine dose, spike protein neutralizing antibody levels were two-fold higher of IgM and 5-fold higher of IgG, exceeding titers of non-vaccinated SARS-CoV-2-naive control. Pfizer vaccine type against COVID-19 gave the highest IgM and IgG titers during the 6 months' trial, with the lowest declining rate. AstraZeneca vaccine type provided an intermediate IgM and IgG titer with a rapid declining rate, while Sino pharm vaccine offered a low IgM and IgG titers with slowly decreasing rate with time.